Skip to navigation Skip to main content Skip to footer

Approved Research

Risk of cardiovascular disease and all-cause/cause-specific mortality in patients with Non- alcoholic fatty liver disease.

Principal Investigator: Professor Jun Lyu
Approved Research ID: 62017
Approval date: December 2nd 2020

Lay summary

The aim of our project (estimated duration: 2 years) seeks to understand overall/cause-specific mortality based on the Non-alcoholic fatty liver disease(NAFLD) status of UK population and causal relationship of Non-alcoholic fatty liver disease(NAFLD) with cardiovascular disease, cancer and premature mortality.

Non-alcoholic fatty liver disease(NAFLD) has significantly increased in prevalence in parallel with increasing obesity and other components of metabolic syndrome. Conversely, those with obesity, metabolic syndrome, dyslipidemia, and diabetes have the greatest risk for Non-alcoholic fatty liver disease(NAFLD). The causal relationships of these diseases are controversial. Patients with Non-alcoholic fatty liver disease(NAFLD) have higher overall mortality, particularly from cardiovascular disease, cancer, and complications of liver diseases. Experimental evidence also illustrates that Non-alcoholic fatty liver disease(NAFLD) is associated with immune response regulation and prothrombotic state. Therefore, solid and thorough population researches of all-cause/cause-specific mortality in patients with Non-alcoholic fatty liver disease(NAFLD) are needed.

The potential to shed light on the underlying association of Non-alcoholic fatty liver disease(NAFLD) with other closely related diseases will stress the importance of population-based interventions in the UK. Such intervention will improve the prevention strategies for Non-alcoholic fatty liver disease(NAFLD) related diseases and reduce social financial burden on healthcare.